429 related articles for article (PubMed ID: 33643442)
1. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Qu J; Mei Q; Liu L; Cheng T; Wang P; Chen L; Zhou J
Ther Adv Med Oncol; 2021; 13():1758835921992968. PubMed ID: 33643442
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
3. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
Dempke WCM; Fenchel K; Dale SP
Transl Lung Cancer Res; 2018 Sep; 7(Suppl 3):S275-S279. PubMed ID: 30393621
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics.
Abaza A; Sid Idris F; Anis Shaikh H; Vahora I; Moparthi KP; Al Rushaidi MT; Muddam MR; Obajeun OA; Jaramillo AP; Khan S
Cureus; 2023 Sep; 15(9):e44582. PubMed ID: 37667784
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.
Niu M; Yi M; Li N; Luo S; Wu K
Exp Hematol Oncol; 2021 Mar; 10(1):18. PubMed ID: 33653420
[TBL] [Abstract][Full Text] [Related]
12. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
13. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
14. Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer.
Shukuya T; Carbone DP
J Thorac Oncol; 2016 Jul; 11(7):976-88. PubMed ID: 26944305
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.
García Campelo MR; Arriola E; Campos Balea B; López-Brea M; Fuentes-Pradera J; de Castro Carpeno J; Aguado C; Pérez Parente D; de Oro Pulido F; Ruiz-Gracia P; Rodríguez-Abreu D
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640601
[TBL] [Abstract][Full Text] [Related]
16. Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC.
Bie F; Tian H; Sun N; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhou B; Gao S
Front Oncol; 2022; 12():769124. PubMed ID: 35223466
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
[TBL] [Abstract][Full Text] [Related]
18. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
20. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Wu S; Hu C; Wu F; Wu Y; Liu P
Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):440-448. PubMed ID: 31315783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]